

**: 616.1/.4 - 06 - 085.322**

- 
- 2
- 1
- 1
- 
- 1
- 2


$$\left( \frac{1}{2} \right)$$

comorbid conditions), (comorbid oliseases, (comorbidity), - (multimorbidity) [12, 14, 16, 33].

[17, 19]:

 $1/3$ 

"?

[4, 5].

[31, 32].

[1, 7,

8, 15, 29].

2-4

, 5-7 -

8-10

70

40-

50-60

[3, 6, 8].

$$\vdots$$
$$).$$

8. , - .

( , , ), [2],

1.

( ) 10-

, 20% - , 14% - , 12% - [11]. 60% , 20% - , 16% - , 10% -

( ). 10% 19 80% [20, 22, 27, 28].

2.

(1996)

1. ( . )

2. ( ).

3.

4. ( ) ,

5. , ( , -

6. ( , ) 4 8 55, 64,5 82,3% , [19].

7. ( , , - 3

).

1.		
2.		
3.		,
4.	„ ”	,
5.	-, ,	, ,
6.	.	

4. , [21, 23, 35].

8.

[22, 27, 28].

5.

[23, 31].

9.

[21].

1 2009-2010 [33, 35].

10.

6.

11.

( ) [1, 2, 23].

7.

[21, 23, 35],

2-2,5

2,5-3,3 - 2,5-3 - 2,2-3 [18],

60-79 - 3 ; - 50-59 - 1 -2

- 2 , 70-79 - 3 , 80 - 4

77

2-

- 3 - 3 - 2

- 1 , - 1 . - 10 ( , ) [24, 25, 30, 34].

: , - , 3

. , -

. [19, 26], - , . -

4 3- - , -

55%, 6 - 65%, 6-8 , -

- 82%, - , -

(Cumulative illness rating scale - CIRS) - , -

( ) -

(Index Coexisting Disease - ICED), -

; : , -

, , - , -

, - , -

- . , -

( ) - , ,

, - ( . 1, 23, .1).

[19, 21, 35]. ( , , -

), , -

: , - , ( )

, , - , ,

, , - .

[6]. . 3 4 ( .1). ,

- , ,

- , -

, -

( ), , - - . ,

[21, 23, 27, 29, 33].

, ( )

[25, 30, 34]. , 2000 , ;

, , , ,

1993 300, 2000 - 2800, 2007 - 16800, : ,

2010 - 22000 [5]. - ,

1. ... 2009.- 12.- .69-71.
2. ... 2010.-300 .
3. ... 2004- 9- .71-74.
4. ... 2007- 2 .
5. ... 2010.- 3- .96-105.
6. ... 2002. — 352 .
7. ... 2010.- 3- .96-105.
8. ... 2009, 6.-C.S1-S3.
9. AHA/NKF. Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease.//Circul.- 2006;Vol. 114: - P.10S3-10S7.
10. Aronow W.S. Prevalence of CAD, complex ventricular arrhythmias, and silent myocardial ischemia and incidence of new coronary events in older persons with chronic renal insufficiency and with normal renal function.// W.S. Aronow[et.al.]-Am J Card. 2000;Vol.S6-P.1142-1143.
11. Australian Institute of Health and Welfare (AIHW): Chronic diseases and associated risk factors in Australia.- Canberra, ACT; 2006. ,
12. Bayliss E.A. Descriptions of Barriers to Self-Care by Persons with Comorbid Chronic Diseases.//E.A. Bayliss, J.F. Steiner, D.H. Fernald [et al.]- Ann Fam. Med.-2003, Vol.1 1.-P.13-21.
13. Bauml S. Heilpflanzen Praxis Heute. — Urban u. Fischer, Mmchen, 2007 - 9S9 S.
14. Bont J. Is co-morbidity taken into account in the antibiotic management of elderly patients with acute bronchitis and COPD exacerbations?// J. Bont, E. Hak, C.E. Birkhoff [et al.] //Fam.Pract. - 2007.Vol 24 4,317-322.
15. Boyd C.M. Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid Diseases: Implications for Pay for Performance. / C.M. Boyd, J. Darer, C. Boulton [et al.] // JAMA.- 2007 ;294(6):716-724.
16. Braithwaite R.S. A Framework for Tailoring Clinical Guidelines to Comorbidity at the Point of Care. /R.S. Braithwaite, J. Concato, C.C. Chang [et al.]//Arch. Intern. Med.-2007,Vol. 167 21.P.2361-2365.
17. Caughey G.E. Prevalence of comorbidity of chronic diseases in Australia. / G.E. Caughey, A.I. Vitry, A.L. Gilbert, E.E. Roughead //BMC Public Health.- 2008, 8.-P.221.
18. Charlson M.E. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. /M.E. Charlson, P. Pompei, K.L. Ales, C.R. McKenzie //J. Chron. Dis.- 1987, Vol.40 5, -F. 373- 383.
19. De Groot V., Beckerman H., Lankhorst G., et al. How to measure comorbidity: a critical review of available methods. / V. De Groot, H. Beckerman, G. Lankhorst [ et al.] // J Clin. Epidemiol.- 2003, Vol.56 P.221-229.
20. Edmondstone W.M. Chest pain and non-respiratory symptoms in acute asthma. / W.M. Edmondstone //Postgrad. Med. J.-2000, Vol.76 897.-F.413-414.
21. Gonzalez A. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? /A. Gonzalez, H.M. Kremers, C.S. Crowson [et al.]//Ann. Rheum. Dis.- 2008, 67.-F.64-69.
22. Kiss D. Bronchial asthma causing symptoms suggestive of angina pectoris. /D. Kiss, W. Veegh, D. Schragel [ et al.] //Eur. Respir. J.- 2003, Vol.21, 3.P.473-477.
23. Kongkaew C. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. / C. Kongkaew, P.R. Noyce, D.M. Ashcroft //Ann. Pharmacother.- 2008, Vol. 42 7, -P.1017-1025.
24. Loew D. EBM: Evidens-based (Phyto) Medicine Versus Experience-based (Phyto) Medicine. / D. Loew // Z. Phytother. 2000 - Vol.21, 2 - P. 71-77.
25. Loew D. Wisksamkeit und Sicherheit praxiszele vanter Phytopharmaka. /D. Loew // Z. Phytother.- 2005-Vol.26, 3 - P. 119-126.
26. Marti S. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. / S. Marti, X. Munoz, J. Rios [et al.] // Eur Respir. J.-2006, Vol. 27, 4.P.689-696.
27. Sin D.D. Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Morbidity and Mortality. /D.D. Sin, S.F.P. Man // Proc. Am. Thorac. Soc.-2005, 2-P.8-1 1.
28. Salpeter S.R. Meta-Analysis: Effect of Long-Acting [beta]- Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths. / S.R. Salpeter, N.S. Buckley, T.M. Ormiston [et al.] - Ann. Intern. Med.// 2006, Vol.144. -P.904-912.
29. Van den Akker M. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. / M. Van den Akker, F. Buntinx, J.F. Metsemakers [et al.] //- J Clin Epidemiol.- 1998, Vol.51, 5.F.367-375.
30. Schulz V. Arzneimittelinteraktion: Relevanz fur Phytopharmaka / V. Schulz //Z. Phytother.- 2004 - Vol.25, 6 - P. 283-288.
31. Starfield B. Comorbidity: Implications for the Importance of Primary Care in 'Case Management. /B. Starfield, K.W. Lemke, T. Bernhardt [ et al.]

//Ann. Fam. Med.-2003,Vol.1 1.P.8-14.

32 Struijs J.N. Comorbidity in patients with diabetes mellitus: impact on medical health care utilization. /J.N. Struijs, C.A. Baan, F.G. Schellevis [ et al.]/BMC Health ServRes.- 2006. 6-P.84.

33 Wang P.S. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. / P.S. Wang, J. Avorn, M.A. Brookhart [et al.]/Hypertension.- 2005. Vol.,46, 2.-P.273-279.

34 WagnerH. NeveEntwicklungen undErgebnisse der phytomedizinischen Forschung. /H. Wagner //Z. Phytother. - 2002 - Vol.23, 4 - P. 164-168.

35 Van Weel C., Schellevis F.G. Comorbidity and guidelines: conflicting interests. /C. Van Weel, F.G. Schellevis //Lancet.- 2006, 36. — P.550-551.

26.11.2012

: 616.1/4 - 06 - 085.322

**O.I.Voloshyn, T.P.Garnyk, L.O.Voloshyna, V.L. Vasyuk**  
**THE APPLICATION OF HERBAL REMEDIES IN CLINICS**  
**OF INTERNAL DISEASES AS ONE OF IMPORTANT WAY OF**  
**SOLUTION OF COMORBIDITY PROBLEMS**  
**(REVIEW OF LITERATURE AND ORIGINAL INVESTIGATION)**

**Key words:** comorbidity, diseases of internal organs, treatment, application of herbal origin remedies.

The problem of comorbidity in clinics of internal medicine, the common non-specific pathophysiological links lying in basis of comorbidity, debatable questions of diagnostics, treatment and prognostic tendencies had been considered. The application of herbal origin remedies in contemporary standards of therapy is considered as one of the most important ways of improvement of treatment results in patients with comorbidity conditions. The necessity of further researches of comorbidity diseases, making supplements in existing treatment standards of diseases of internal organs in type of multicomponent herbal remedies, professional training of physicians of general practice-family medicine in branch of phytotherapy are grounded.

616.36-002.576.343-57.05-12

- 1 . . . , . . . ” . . . ” . . .
  - 2 . . . , . . . ” . . . . .
  - 2 . . . , . . . ” . . . . .
  - 2 . . . , . . . ” . . . . .
  - 1 . . . , . . . ” . . . . .
- 1 ‘ « »
- 2 « »

( ) [22, 29, 30].

[9, 34].